This CEO is Fighting Parkinson’s And Other Neuro-Degenerative Diseases – Meet Gain Therapeutics GANX CEO

<p>This CEO is Fighting Parkinson’s And Other Neuro-Degenerative Diseases – Meet Gain Therapeutics GANX CEO</p><p><br></p><p>Guest: </p><p>Gene Mack, CEO, Gain Therapeutics</p><p><br></p><p>Guest’s Bio: </p><p>Gene Mack serves as Chief Executive Officer and President of Gain Therapeutics. He joined the Company in April 2024 and brings 25 years of experience in the life sciences sector spanning clinical research, financing and capital markets, investing, corporate strategy and business development. Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023. </p><p><br></p><p>Previous to Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of Merck &amp; Co’s (MSD) $475 million acquisition of OncoImmune in 2020 where he had also been CFO. Before that, he has held the CFO role for several development- and commercial-stage biopharmaceutical companies, raising over $350 million in IPO and other equity transactions. </p><p><br></p><p>Prior to his operational experience, Gene covered the biotechnology and life sciences sector as a senior publishing analyst at various investment banks, including Gruntal &amp; Co, Lazard, Mizuho, and HSBC. Gene received both his B.S. in Biochemistry and M.B.A. in Finance from Fordham University.</p><p><br></p><p>Company: </p><p>Gain Therapeutics ($GANX)</p><p><br></p><p>Company Description: </p><p>Gain Therapeutics, a clinical-stage biotechnology company headquartered in Bethesda focused on developing novel allosteric small molecule therapies for neurodegenerative diseases.</p><p><br></p><p>Under Gene’s leadership, the company is advancing its lead candidate, GT-02287, with recent Phase 1b data presented at AD/PD 2026 demonstrating encouraging biomarker improvements, including reductions in DDC and glucosylsphingosine, as well as durable clinical outcomes through 150 days of treatment in Parkinson’s disease.</p><p><br></p>